BDSX
Biodesix, Inc.
Price Chart
Latest Quote
$15.22
-0.11 (-0.72%)
Current Price
| Previous Close | $15.33 |
| Open | $15.33 |
| Day High | $15.98 |
| Day Low | $15.21 |
| Volume | 185,317 |
Stock Information
| Shares Outstanding | 10.36M |
| Total Debt | $73.57M |
| Cash Equivalents | $25.57M |
| Revenue | $96.10M |
| Net Income | $-31.96M |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | $157.62M |
| EPS (TTM) | $-3.96 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $202.96M |
| Sales | $96.10M |
| Income | $-31.96M |
| Book/sh | $0.90 |
| Cash/sh | $2.47 |
| Employees | 334 |
Financial Ratios
| Quick Ratio | 2.42 |
| Current Ratio | 2.82 |
| Debt/Eq | 805.61 |
Returns & Margins
| ROA | -17.48% |
| ROE | -316.53% |
| Gross Margin | 81.66% |
| Operating Margin | -25.81% |
| Profit Margin | -33.26% |
Ownership
| Insider Ownership | 41.93% |
| Institutional Ownership | 38.76% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -69.18 |
| P/S | 1.64 |
| P/B | 16.84 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $29.60 |
Technical Indicators
| SMA20 | $15.33 |
| SMA50 | $13.95 |
| SMA200 | $10.76 |
| RSI | 43.90 |
| ATR | 1.0421 |
| Shares Float | 4.99M |
| Short Float | 1.80% |
| Short Ratio | 1.36 |
| Volatility | 0.59 |
| Rel Volume | 3.67 |
Performance History
| Week | +1.40% |
| Month | +6.81% |
| Quarter | -5.41% |
| 6 Months | +102.39% |
| YTD | +135.60% |
| Year | +164.24% |
| 3 Years | -47.52% |
| 5 Years | -95.00% |
| 10 Years | -94.06% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $15.22 | 185,400 |
| 2026-06-16 | $15.33 | 20,400 |
| 2026-06-15 | $15.60 | 36,100 |
| 2026-06-12 | $15.06 | 21,100 |
| 2026-06-11 | $14.80 | 129,900 |
| 2026-06-10 | $15.01 | 29,100 |
| 2026-06-09 | $15.36 | 22,100 |
| 2026-06-08 | $14.95 | 22,300 |
| 2026-06-05 | $15.46 | 33,900 |
| 2026-06-04 | $16.50 | 41,700 |
| 2026-06-03 | $16.10 | 20,800 |
| 2026-06-02 | $15.44 | 47,200 |
| 2026-06-01 | $15.27 | 38,500 |
| 2026-05-29 | $16.32 | 106,800 |
| 2026-05-28 | $15.99 | 120,500 |
| 2026-05-27 | $14.81 | 43,000 |
| 2026-05-26 | $14.81 | 30,000 |
| 2026-05-22 | $14.93 | 30,200 |
| 2026-05-21 | $15.18 | 17,800 |
| 2026-05-20 | $14.37 | 13,600 |
| 2026-05-19 | $13.94 | 37,000 |
| 2026-05-18 | $14.25 | 29,700 |
About Biodesix, Inc.
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
đ° Latest News
Are Medical Stocks Lagging Biodesix (BDSX) This Year?
Zacks âĸ 2026-06-15T13:40:04Z
Zacks Industry Outlook Highlights BrightSpring Health Services, Biodesix and HealthEquity
Zacks âĸ 2026-06-09T11:16:00Z
3 Medical Service Industry Stocks Thriving Amid Workforce Challenges
Zacks âĸ 2026-06-08T12:22:00Z
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
Zacks âĸ 2026-05-28T13:40:01Z
Wall Street Analysts Believe Biodesix (BDSX) Could Rally 104.29%: Here's is How to Trade
Zacks âĸ 2026-05-25T13:55:03Z
Canaccord Lifts PT on Biodesix (BDSX) on Raised Revenue Assumptions
Insider Monkey âĸ 2026-05-23T12:16:59Z
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
Zacks âĸ 2026-05-12T13:40:03Z
Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect?
Zacks âĸ 2026-05-07T13:55:03Z
Biodesix, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-05T00:16:35Z
Biodesix (BDSX) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-04T22:26:03Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $16,719,000 | $15,573,000 | $13,010,000 | $14,154,000 |
| Cost Of Revenue | $16,719,000 | $15,573,000 | $13,010,000 | $14,154,000 |
| Total Revenue | $88,499,000 | $71,323,000 | $49,087,000 | $38,212,000 |
| Operating Revenue | $88,499,000 | $71,323,000 | $49,087,000 | $38,212,000 |
| Expenses | ||||
| Interest Expense | $7,716,000 | $8,258,000 | $9,536,000 | $8,072,000 |
| Total Expenses | $116,265,000 | $105,583,000 | $90,385,000 | $88,718,000 |
| Other Income Expense | $217,000 | $-413,000 | $-1,312,000 | $-6,869,000 |
| Other Non Operating Income Expenses | $604,000 | $73,000 | $6,000 | $109,000 |
| Net Non Operating Interest Income Expense | $-7,716,000 | $-8,258,000 | $-9,536,000 | $-8,072,000 |
| Interest Expense Non Operating | $7,716,000 | $8,258,000 | $9,536,000 | $8,072,000 |
| Operating Expense | $99,546,000 | $90,010,000 | $77,375,000 | $74,564,000 |
| Selling And Marketing Expense | - | - | - | $61,462,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-35,265,000 | $-42,931,000 | $-52,146,000 | $-65,447,000 |
| Net Interest Income | $-7,716,000 | $-8,258,000 | $-9,536,000 | $-8,072,000 |
| Normalized Income | $-34,878,000 | $-42,445,000 | $-50,828,000 | $-58,469,000 |
| Net Income From Continuing And Discontinued Operation | $-35,265,000 | $-42,931,000 | $-52,146,000 | $-65,447,000 |
| Total Operating Income As Reported | $-27,873,000 | $-34,498,000 | $-41,342,000 | $-50,587,000 |
| Net Income Common Stockholders | $-35,265,000 | $-42,931,000 | $-52,146,000 | $-65,447,000 |
| Net Income | $-35,265,000 | $-42,931,000 | $-52,146,000 | $-65,447,000 |
| Net Income Including Noncontrolling Interests | $-35,265,000 | $-42,931,000 | $-52,146,000 | $-65,447,000 |
| Net Income Continuous Operations | $-35,265,000 | $-42,931,000 | $-52,146,000 | $-65,447,000 |
| Pretax Income | $-35,265,000 | $-42,931,000 | $-52,146,000 | $-65,447,000 |
| Special Income Charges | $-107,000 | $-486,000 | $-44,000 | $-7,062,000 |
| Operating Income | $-27,766,000 | $-34,260,000 | $-41,298,000 | $-50,506,000 |
| Gross Profit | $71,780,000 | $55,750,000 | $36,077,000 | $24,058,000 |
| Per Share | ||||
| Diluted EPS | $-4.67 | $-6.60 | $-12.80 | $-31.00 |
| Basic EPS | $-4.67 | $-6.60 | $-12.80 | $-31.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-21,561,000 | $-28,731,000 | $-35,785,000 | $-44,553,000 |
| Total Unusual Items | $-387,000 | $-486,000 | $-1,318,000 | $-6,978,000 |
| Total Unusual Items Excluding Goodwill | $-387,000 | $-486,000 | $-1,318,000 | $-6,978,000 |
| Reconciled Depreciation | $5,601,000 | $5,456,000 | $5,507,000 | $5,844,000 |
| EBITDA (Bullshit earnings) | $-21,948,000 | $-29,217,000 | $-37,103,000 | $-51,531,000 |
| EBIT | $-27,549,000 | $-34,673,000 | $-42,610,000 | $-57,375,000 |
| Diluted Average Shares | $7,551,000 | $6,483,500 | $4,105,650 | $2,105,150 |
| Basic Average Shares | $7,551,000 | $6,483,500 | $4,105,650 | $2,105,150 |
| Diluted NI Availto Com Stockholders | $-35,265,000 | $-42,931,000 | $-52,146,000 | $-65,447,000 |
| Impairment Of Capital Assets | $107,000 | $238,000 | $44,000 | $81,000 |
| Gain On Sale Of Security | $-280,000 | - | $-1,274,000 | $84,000 |
| Research And Development | $12,001,000 | $9,559,000 | $9,988,000 | $13,102,000 |
| Selling General And Administration | $87,545,000 | $80,451,000 | $67,387,000 | $61,462,000 |
| Other Special Charges | - | $248,000 | - | $6,981,000 |
| Restructuring And Mergern Acquisition | - | - | - | $0 |
Fetched: 2026-06-12
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-21,379,000 | $-29,000 | $-18,362,000 | $-4,222,000 |
| Total Assets | $87,476,000 | $97,244,000 | $99,096,000 | $92,906,000 |
| Total Non Current Assets | $54,958,000 | $57,760,000 | $59,413,000 | $39,572,000 |
| Other Non Current Assets | $8,230,000 | $7,260,000 | $6,859,000 | $5,923,000 |
| Goodwill And Other Intangible Assets | $18,914,000 | $20,905,000 | $22,942,000 | $24,828,000 |
| Other Intangible Assets | $3,883,000 | $5,874,000 | $7,911,000 | $9,797,000 |
| Current Assets | $32,518,000 | $39,484,000 | $39,683,000 | $53,334,000 |
| Other Current Assets | $4,495,000 | $4,636,000 | $5,720,000 | $5,181,000 |
| Receivables | $9,036,000 | $8,603,000 | $7,679,000 | $5,065,000 |
| Accounts Receivable | $9,036,000 | $8,603,000 | $7,679,000 | $5,065,000 |
| Allowance For Doubtful Accounts Receivable | $-62,000 | $-481,000 | $-65,000 | $-118,000 |
| Gross Accounts Receivable | $9,098,000 | $9,084,000 | $7,744,000 | $5,183,000 |
| Cash Cash Equivalents And Short Term Investments | $18,987,000 | $26,245,000 | $26,284,000 | $43,088,000 |
| Cash And Cash Equivalents | $18,987,000 | $26,245,000 | $26,284,000 | $43,088,000 |
| Debt | ||||
| Net Debt | $28,464,000 | $10,184,000 | $8,992,000 | - |
| Total Debt | $72,854,000 | $61,976,000 | $60,691,000 | $31,850,000 |
| Long Term Debt And Capital Lease Obligation | $71,484,000 | $61,236,000 | $60,388,000 | $30,258,000 |
| Long Term Debt | $47,445,000 | $36,408,000 | $35,225,000 | $25,004,000 |
| Current Debt And Capital Lease Obligation | $1,370,000 | $740,000 | $303,000 | $1,592,000 |
| Current Debt | $6,000 | $21,000 | $51,000 | $49,000 |
| Other Current Borrowings | $6,000 | $21,000 | $51,000 | $49,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $89,941,000 | $76,368,000 | $94,516,000 | $72,300,000 |
| Total Non Current Liabilities Net Minority Interest | $72,505,000 | $62,051,000 | $61,100,000 | $49,461,000 |
| Other Non Current Liabilities | $1,021,000 | $815,000 | $712,000 | $19,203,000 |
| Current Liabilities | $17,436,000 | $14,317,000 | $33,416,000 | $22,839,000 |
| Other Current Liabilities | $992,000 | $641,000 | $22,150,000 | $10,382,000 |
| Current Deferred Liabilities | $961,000 | $678,000 | $324,000 | $962,000 |
| Payables And Accrued Expenses | $6,279,000 | $5,488,000 | $6,784,000 | $5,232,000 |
| Payables | $3,080,000 | $2,194,000 | $2,929,000 | $1,685,000 |
| Accounts Payable | $3,080,000 | $2,194,000 | $2,929,000 | $1,685,000 |
| Equity | ||||
| Common Stock Equity | $-2,465,000 | $20,876,000 | $4,580,000 | $20,606,000 |
| Total Equity Gross Minority Interest | $-2,465,000 | $20,876,000 | $4,580,000 | $20,606,000 |
| Stockholders Equity | $-2,465,000 | $20,876,000 | $4,580,000 | $20,606,000 |
| Retained Earnings | $-497,762,000 | $-462,497,000 | $-419,566,000 | $-367,420,000 |
| Other | ||||
| Ordinary Shares Number | $8,253,053 | $7,274,578 | $4,811,794 | $3,880,717 |
| Share Issued | $8,253,053 | $7,274,578 | $4,811,794 | $3,880,717 |
| Tangible Book Value | $-21,379,000 | $-29,000 | $-18,362,000 | $-4,222,000 |
| Invested Capital | $44,986,000 | $57,305,000 | $39,856,000 | $45,659,000 |
| Working Capital | $15,082,000 | $25,167,000 | $6,267,000 | $30,495,000 |
| Capital Lease Obligations | $25,403,000 | $25,547,000 | $25,415,000 | $6,797,000 |
| Total Capitalization | $44,980,000 | $57,284,000 | $39,805,000 | $45,610,000 |
| Additional Paid In Capital | $495,289,000 | $483,366,000 | $424,050,000 | $387,948,000 |
| Capital Stock | $8,000 | $7,000 | $96,000 | $78,000 |
| Common Stock | $8,000 | $7,000 | $96,000 | $78,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $24,039,000 | $24,828,000 | $25,163,000 | $5,254,000 |
| Current Deferred Revenue | $961,000 | $678,000 | $324,000 | $962,000 |
| Current Capital Lease Obligation | $1,364,000 | $719,000 | $252,000 | $1,543,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $7,834,000 | $6,770,000 | $3,855,000 | $4,671,000 |
| Current Accrued Expenses | $3,199,000 | $3,294,000 | $3,855,000 | $3,547,000 |
| Goodwill | $15,031,000 | $15,031,000 | $15,031,000 | $15,031,000 |
| Net PPE | $27,814,000 | $29,595,000 | $29,612,000 | $8,821,000 |
| Accumulated Depreciation | $-12,516,000 | $-9,134,000 | $-5,612,000 | $-7,018,000 |
| Gross PPE | $40,330,000 | $38,729,000 | $35,224,000 | $15,839,000 |
| Leases | $28,265,000 | $28,192,000 | $24,713,000 | $2,365,000 |
| Construction In Progress | $27,000 | $89,000 | $0 | $2,947,000 |
| Other Properties | $9,420,000 | $7,621,000 | $7,834,000 | $9,008,000 |
| Machinery Furniture Equipment | $2,618,000 | $2,827,000 | $2,677,000 | $1,519,000 |
| Properties | $0 | $0 | $0 | $0 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-12
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-23,674,000 | $-52,089,000 | $-45,932,000 | $-48,506,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-23,271,000 | $-48,649,000 | $-22,870,000 | $-44,972,000 |
| Cash Flow From Continuing Operating Activities | $-23,271,000 | $-48,649,000 | $-22,870,000 | $-44,972,000 |
| Operating Gains Losses | $280,000 | $248,000 | $1,274,000 | $6,897,000 |
| Investing Activities | ||||
| Capital Expenditure | $-403,000 | $-3,440,000 | $-23,062,000 | $-3,534,000 |
| Investing Cash Flow | $-403,000 | $-3,440,000 | $-23,062,000 | $-3,534,000 |
| Cash Flow From Continuing Investing Activities | $-403,000 | $-3,440,000 | $-23,062,000 | $-3,534,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $7,320,000 | $55,625,000 | $28,126,000 | $59,538,000 |
| Financing Cash Flow | $16,417,000 | $52,050,000 | $29,129,000 | $58,882,000 |
| Cash Flow From Continuing Financing Activities | $16,417,000 | $52,050,000 | $29,129,000 | $58,882,000 |
| Net Other Financing Charges | $-1,379,000 | $-4,174,000 | $-9,682,000 | $-17,778,000 |
| Net Common Stock Issuance | $7,320,000 | $55,625,000 | $28,126,000 | $59,538,000 |
| Common Stock Issuance | $7,320,000 | $55,625,000 | $28,126,000 | $59,538,000 |
| Other | ||||
| Repayment Of Debt | $-21,000 | $-51,000 | $-49,000 | $-28,604,000 |
| Issuance Of Debt | $10,000,000 | $0 | $10,000,000 | $45,102,000 |
| Interest Paid Supplemental Data | $6,398,000 | $7,024,000 | $3,994,000 | $1,009,000 |
| End Cash Position | $19,075,000 | $26,332,000 | $26,371,000 | $43,174,000 |
| Beginning Cash Position | $26,332,000 | $26,371,000 | $43,174,000 | $32,798,000 |
| Changes In Cash | $-7,257,000 | $-39,000 | $-16,803,000 | $10,376,000 |
| Proceeds From Stock Option Exercised | $497,000 | $650,000 | $734,000 | $624,000 |
| Net Issuance Payments Of Debt | $9,979,000 | $-51,000 | $9,951,000 | $16,498,000 |
| Net Long Term Debt Issuance | $9,979,000 | $-51,000 | $9,951,000 | $16,498,000 |
| Long Term Debt Payments | $-21,000 | $-51,000 | $-49,000 | $-28,604,000 |
| Long Term Debt Issuance | $10,000,000 | $0 | $10,000,000 | $45,102,000 |
| Net Intangibles Purchase And Sale | $-144,000 | $-210,000 | $-143,000 | $-236,000 |
| Purchase Of Intangibles | $-144,000 | $-210,000 | $-143,000 | $-236,000 |
| Net PPE Purchase And Sale | $-259,000 | $-3,230,000 | $-22,919,000 | $-3,298,000 |
| Purchase Of PPE | $-259,000 | $-3,230,000 | $-22,919,000 | $-3,298,000 |
| Change In Working Capital | $334,000 | $-21,669,000 | $-7,019,000 | $-6,815,000 |
| Change In Other Working Capital | $174,000 | $248,000 | $-755,000 | $-1,213,000 |
| Change In Other Current Liabilities | $-789,000 | $-22,527,000 | $-2,997,000 | $-937,000 |
| Change In Other Current Assets | $-379,000 | $784,000 | $938,000 | $-2,391,000 |
| Change In Payables And Accrued Expense | $1,859,000 | $1,637,000 | $513,000 | $-773,000 |
| Change In Receivables | $-531,000 | $-1,811,000 | $-4,718,000 | $-1,501,000 |
| Changes In Account Receivables | $-531,000 | $-1,811,000 | $-4,718,000 | $-1,501,000 |
| Other Non Cash Items | $1,353,000 | $2,484,000 | $23,600,000 | $8,414,000 |
| Stock Based Compensation | $4,139,000 | $6,638,000 | $5,373,000 | $5,961,000 |
| Provisionand Write Offof Assets | $180,000 | $887,000 | $497,000 | $93,000 |
| Asset Impairment Charge | $107,000 | $238,000 | $44,000 | $81,000 |
| Depreciation Amortization Depletion | $5,601,000 | $5,456,000 | $5,507,000 | $5,844,000 |
| Depreciation And Amortization | $5,601,000 | $5,456,000 | $5,507,000 | $5,844,000 |
| Depreciation | $5,601,000 | $5,456,000 | $5,507,000 | $5,844,000 |
| Gain Loss On Investment Securities | $280,000 | - | $1,274,000 | $-84,000 |
| Net Income From Continuing Operations | $-35,265,000 | $-42,931,000 | $-52,146,000 | $-65,447,000 |
| Income Tax Paid Supplemental Data | - | - | - | $0 |
| Net Business Purchase And Sale | - | - | - | - |
| Purchase Of Business | - | - | - | - |
Fetched: 2026-06-12